memo inOncology SPECIAL ISSUE congress report ASCO 2021– Lung Cancer is now available!
This report highlights immunotherapeutic standards in early-stage lung cancer. Moreover, strategies against sensitizing and resistance-mediating EGFR mutations as well as current perspectives regarding KRAS, MET, ROS1 and HER2 mutations are covered. Furthermore, immunotherapies and immunosupportive mechansims via e.g. anti-angiogenesis are addressed. Last but not least, this special issue includes a section about new vistas for patients with SCLC and expert interviews regarding resistance as one of the biggest challenges with targeted therapies.
As an additional feature, you will find expert video interviews with Martin Reck, Luis Paz-Ares, David T. Cooke, Donald Harvey, and Ferdinandos Skoulidis on different conference highlights on our website.
Access an article directly (English):
- Preface ASCO 2021
- Early-stage lung cancer: immunotherapeutic standards
- EGFR-mutant disease: strategies against sensitizing and resistance-mediating mutations
- KRAS, MET, ROS1, HER2: current perspectives
- Immunotherapy: from predictive factors to antibiotics
- How does checkpoint inhibition perform in the setting of oncogene-driven lung cancer?
- Enhancing immunosupportive mechanisms via anti-angiogenesis
- Opening up new vistas for patients with SCLC
- Resistance is all too often looming with targeted therapies
- Full Report (English)
|Download the full report (English)|
The memo inOncology Special Issue report is produced by Springer, as a supplement of memo (the Magazine of European Medical Oncology) and sponsored by Boehringer Ingelheim and BeiGene with an unrestricted educational grant. For more information on the memo inOncology Special Issue series, and for free access to all previous editions, visit the memo-inOncology website.